Clinical utility of CD23 and FMC7 antigen coexistent expression in B-cell lymphoproliferative disorder subclassification

被引:23
作者
Ahmad, E [1 ]
Garcia, D [1 ]
Davis, BH [1 ]
机构
[1] William Beaumont Hosp, Dept Clin Pathol, Royal Oak, MI 48072 USA
来源
CYTOMETRY | 2002年 / 50卷 / 01期
关键词
flow cytometry; leukemia; lymphoma; monoclonal gammopathy; immunophenotype; phenotype; diagnostic immunology; disease classification;
D O I
10.1002/cyto.10045
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Background: CD23 and FMC7 are normal B-cell antigens utilized during diagnostic immunophenotyping of suspected lymphoproliferative disorders. However, the diagnostic utility of coexistent antigenic expression patterns with simultaneous two-color staining and flow cytometric analysis has not been studied extensively. Methods: Using multiparameter flow cytometry, we evaluated the expression pattern of FMC7 and CD23 in 218 cases of B-cell lymphoma from blood and bone marrow specimens. Results: The CD23(+)/FMC7(-) pattern was the most common pattern in patients with chronic lymphocytic leukemia and related variants. The widest variation of patterns was found in patients with follicular cell lymphoma, large cell lymphoma, and Waldenstrom's macroglobulinemia, a lymphoplasmacytoid disorder, although most cases expressed the CD23-/FMC7(+) pattern. The CD23 and FMC7 antigen, along with the CD5 coexpression pattern, provides critical adjunctive data. These data allow accurate classification of the majority of cases, thereby providing a key aspect of a reliable diagnostic algorithm. The CD23 and FMC7 antigen expression pattern, along with selected other antigens, was predictive of subtypes in >95% of lymphoproliferative cases and narrowed the differential diagnosis in the remaining cases. Conclusion: The flow cytometric CD23/FMC7 expression pattern achieved by multicolor immunophenotyping facilitates accurate and reproducible classification of B-cell lymphomas and has diagnostic utility. (C) 2002 Wiley-Liss, Inc.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 34 条
[1]  
BATATA A, 1992, CANCER, V70, P2436, DOI 10.1002/1097-0142(19921115)70:10<2436::AID-CNCR2820701009>3.0.CO
[2]  
2-C
[3]  
Braylan RC, 2001, CYTOMETRY, V46, P23, DOI 10.1002/1097-0320(20010215)46:1<23::AID-CYTO1033>3.0.CO
[4]  
2-Z
[5]   Primary nodal marginal zone lymphomas of splenic and MALT type [J].
Campo, E ;
Miquel, R ;
Krenacs, L ;
Sorbara, L ;
Raffeld, M ;
Jaffe, ES .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1999, 23 (01) :59-68
[6]   National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment [J].
Cheson, BD ;
Bennett, JM ;
Grever, M ;
Kay, N ;
Keating, MJ ;
OBrien, S ;
Rai, KR .
BLOOD, 1996, 87 (12) :4990-4997
[7]  
Davis BH, 1997, CYTOMETRY, V30, P249
[8]  
DiGiuseppe JA, 1998, SEMIN ONCOL, V25, P6
[9]  
DORFMAN DM, 1994, MODERN PATHOL, V7, P326
[10]   EXPRESSION OF FMC7 ANTIGEN AND TARTRATE-RESISTANT ACID-PHOSPHATASE ISOENZYME IN CASES OF B-LYMPHOPROLIFERATIVE DISEASES [J].
DREXLER, HG ;
MENON, M ;
GAEDICKE, G ;
MINOWADA, J .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1987, 23 (01) :61-&